Abivax shares surge following positive clinical trial data
French biotechnology firm Abivax has reported that new clinical trial results support the safety and efficacy of its experimental treatment for ulcerative colitis.
AI disclosure: Summarised from a single named source by an AI model with editorial rules; links to the original report.
Shares in French biotech company Abivax rose by 36% on 30 June following the release of new clinical trial data. According to Euronews, the findings provide support for the safety and effectiveness of the firm's experimental drug, obefazimod, which is being developed as a treatment for ulcerative colitis.
Source: Euronews. Read the original report ↗
Source ledger
-
This brief is based on reporting by Euronews.supports: Euronews